Skip to main content
SKYE logo

SKYE · Skye Bioscience, Inc. · Documents

Track SKYE — free
$1.02 -0.01 (-1.36%) Play latest call Q4 2025 earnings call transcript
Market Cap
$4.56M
Shares
4.42M
Volume · Nov 19 12.7K Avg daily vol (62 sessions) 84.15K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $55.92M 10-K filed Mar 10, 2026 Quarterly report New FY2026 Q3 Net income $69.13K 10-Q filed Nov 13, 2026 Latest results Financial results 8-K filed Mar 10, 2026 Earnings call Q4 2025 earnings call Held Mar 10, 2026
2026
Nov 13
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CBeyond halted as Redx deal awaits conditions

Skye Bioscience, Inc. terminated the CBeyond trial, paused nimacimab research and development, and entered a conditional agreement to acquire Redx. Concurrent financing is expected to provide approximately $103.9 million, potentially increasing to $108.9 million.

Net income $69.13K Diluted EPS $0.01
Read from the MD&A section
4 source passages
In the second quarter of 2026, we terminated the CBeyond trial and paused all research and development activities for nimacimab. Unless otherwise provided in this Quarterly Report on Form 10-Q, references to “we,” “us,” “our” and “Skye” in this discussion and analysis refer to Skye Bioscience, Inc., a Nevada corporation, together with its consolidated subsidiaries. On August 14, 2026, we entered into the Transaction Agreement with Redx. Pursuant to the Transaction Agreement, and subject to the terms and conditions set forth therein, we will acquire the entire issued and to be issued share capital of Redx pursuant to a Scheme of Arrangement. The Financing is expected to provide the combined company with an aggregate total gross proceeds of approximately $103.9 million, which may increase to up to $108.9 million, subject to certain conditions set forth in the Side Letter. Open the document at this passage
Nov 12
Proxy statement DEFA14A
Jury returned unanimous verdict for company on all claims

Skye Bioscience, Inc. said a jury returned a unanimous verdict in its favor on all claims in the Wendy Cunning lawsuit on November 10, 2026. Judgment is expected in due course, but the plaintiff may file post-trial motions or appeal.

3 source passages
a former employee of the Company filed a lawsuit, entitled Wendy Cunning vs Skye Bioscience, Inc., in the U.S. District Court for the Central District of California On November 10, 2026, following the retrial in the District Court, the jury returned a unanimous verdict in favor of the Company on all claims. The Company expects the judgement by the District Court will be entered in due course. The plaintiff may file post-trial motions and may appeal any judgment entered on the verdict. Open the document at this passage
Nov 12
Current report 8-K Events of Nov 10
Jury unanimously rules for Skye Bioscience on all claims

Skye Bioscience said a jury returned a unanimous verdict in its favor on all claims in former employee Wendy Cunning’s whistleblower and retaliation lawsuit on November 10, 2026. Judgment is expected soon, but post-trial motions or an appeal remain possible.

Other events
3 source passages
On November 10, 2026, following the retrial in the District Court, the jury returned a unanimous verdict in favor of the Company on all claims. The Company expects the judgement by the District Court will be entered in due course. The plaintiff may file post-trial motions and may appeal any judgment entered on the verdict. Open the document at this passage
Oct 26
Proxy statement PREM14A
Proxy statement

Skye Bioscience proposes acquiring Redx Pharma Limited, renaming the combined company Fibrx Therapeutics, Inc., and seeking stockholder approval for related share issuances, financing, charter amendments, compensation and meeting adjournment.

Read from the first part of this long document
Jun 23
Current report 8-K Events of Jun 18
Other events AI summary on its way
Apr 16
Proxy statement DEF 14A Meeting May 26, 2026
Proxy statement AI summary on its way
Mar 10
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $55.92M Diluted EPS -$1.41
2025
Showing 1–50 of 132 documents
Key facts CIK 1516551 CUSIP 83086J309 13F (30d) 32 filings 29 filers Visit website Investor relations